ResultsIQ

ResultsIQ › Latest results › Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited investor presentation summary

NSE: EMCURE · BSE: 544210

Investor presentation of 6 Nov 2026, summarised by AI from the filing.

The company states the meeting schedule is tentative and may change due to exigencies on the part of investors or the company.

Key takeaways

  1. Tentative schedule The company states the meeting schedule is tentative and may change due to exigencies on the part of investors or the company.
  2. No UPSI No unpublished price sensitive information is proposed to be shared or discussed with the analysts or investors during the meeting.
  3. Filing basis The intimation is filed under Regulation 30 read with Para A of Part A of Schedule III of the SEBI LODR Regulations, 2015.
  4. Signatory The letter is signed by Amruta Yangalwar, Company Secretary and Compliance Officer, ICSI Membership Number A25687.

Original filing on BSE

Emcure Pharmaceuticals Limited Q2 FY27 results

As filed: Revenue ₹2,820 cr (+24% year on year), EBITDA ₹588 cr (+24% year on year), PAT ₹325 cr (+30% year on year), EBITDA margin 20.8% (−13 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹2,580 cr (+23% year on year), EBITDA ₹533 cr (+28% year on year), PAT ₹292 cr (+36% year on year), EBITDA margin 20.6% (+79 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 79 bps year on year. Revenue rose ₹479 cr on a year ago, more than the ₹286 cr it added the year before. Share price after the results: −1.6% in 29 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹2,470 cr (+17% year on year), EBITDA ₹480 cr (+19% year on year), PAT ₹244 cr (+24% year on year), EBITDA margin 19.4% (+37 bps). Score 63 of 100, In line with trend. EBITDA margin rose 37 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.7% in 30 days (Nifty 500: −1.5%).
  • Q3 FY26: Revenue ₹2,363 cr (+20% year on year), EBITDA ₹493 cr (+39% year on year), PAT ₹231 cr (+53% year on year), EBITDA margin 20.9% (+276 bps). Score 82 of 100, Above trend. EBITDA margin rose 276 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.0% in 30 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹2,270 cr (+13% year on year), EBITDA ₹476 cr (+25% year on year), PAT ₹251 cr (+24% year on year), EBITDA margin 21.0% (+199 bps). Score 66 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹2,101 cr (+16% year on year), EBITDA ₹417 cr (+24% year on year), PAT ₹215 cr (+41% year on year), EBITDA margin 19.9% (+128 bps). Score 70 of 100, Above trend. EBITDA margin rose 128 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.5% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹2,116 cr, EBITDA ₹403 cr, PAT ₹197 cr, EBITDA margin 19.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,116 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +22.2% in 29 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,963 cr, EBITDA ₹355 cr, PAT ₹156 cr, EBITDA margin 18.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,963 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Emcure Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.